Furthermore, as COX-2 is more highly expressed in cutaneous melanoma and metastatic melanoma compared with benign naevi (Chwirot and Kuzbicki, 2007), defining upstream regulators could be valuable for drug development. This evidence concerns the gene PTGS2 and cutaneous melanoma.